Abstract:Osimertinib is a 3rd-generation, irreversible, oral EGFR-TKI that potently and selectively inhibits both EGFR-mutated (EGFRm) and EGFR T790M resistance mutations, and has demonstrated efficacy in NSCLC CNS metastases. In the phase III FLAURA study (NCT02296125), osimertinib resulted in significant progression-free survival (PFS) benefit (primary endpoint; datacut off [DCO] 12 June 2017) over comparator EGFR-TKI (HR 0.46, p < 0.001). Overall survival (OS) data were immature (25% maturity) at that time. Here, we report the final OS analysis (58% maturity).Eligible patients (pts): ≥18 years (Japan: ≥20), treatment-naïve with Ex19del/L858R EGFRm advanced NSCLC; WHO performance status 0–1. Pts with stable CNS metastases not requiring steroids for ≥2 weeks were allowed. Pts were randomised 1:1 to osimertinib 80 mg once daily (qd) orally (po) or comparator EGFR-TKI (gefitinib 250 mg qd/erlotinib 150 mg qd po), stratified by mutation status (Ex19del/L858R) and race (Asian/non-Asian). Crossover was allowed for pts in the comparator EGFR-TKI arm upon central confirmation of progression and T790M positivity. Primary endpoint: PFS by RECIST v1.1, per investigator. OS was a secondary endpoint. DCO 25 June 2019.Globally, 556 pts were randomised to osimertinib (n = 279) or comparator EGFR-TKI (n = 277). Per study protocol, 70 (25%) pts crossed over from comparator EGFR-TKI to osimertinib. Osimertinib significantly improved OS vs comparator EGFR-TKI. All causality AEs, per investigator: osimertinib, 98% (grade ≥3, 42%); comparator EGFR-TKI, 98% (grade ≥3, 47%). AEs leading to discontinuation: osimertinib, 15%; comparator EGFR-TKI, 18%. The safety profile appears consistent with previously reported data. LBA5_PROS for patients in the full analysis set was analysed using a log rank test (stratified by race and mutation type) for generation of the p-value and using the Breslow approach for handling ties. The median OS with 95% confidence intervals were calculated by Kaplan Meier technique. For statistical significance, a 2-sided p-value of less than 0.0495, as determined by the O'Brien-Fleming approach was required due the previous interim analysis.*Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive.LBA5_PROS for patients in the full analysis set was analysed using a log rank test (stratified by race and mutation type) for generation of the p-value and using the Breslow approach for handling ties. The median OS with 95% confidence intervals were calculated by Kaplan Meier technique. For statistical significance, a 2-sided p-value of less than 0.0495, as determined by the O'Brien-Fleming approach was required due the previous interim analysis.*Any patient not known to have died at the time of analysis was censored based on the last recorded date on which the patient was known to be alive.Osimertinib provided a statistically significant and clinically meaningful improvement in OS vs comparator EGFR-TKI in first-line pts with EGFRm advanced NSCLC.NCT02296125.Natalie Griffiths, PhD, from iMed Comms, an Ashfield Company; funded by AstraZeneca.AstraZeneca.AstraZeneca.S.S. Ramalingam: Honoraria (self), Advisory / Consultancy: AstraZeneca, Amgen, Bristol-Myers Squibb, Merck, Roche/Genentech, Loxo, Nektar, Tesaro; Research grant / Funding (institution): AstraZeneca, Amgen, Bristol-Myers Squibb, Merck, Tesaro, Advaxis, Takeda. J.E. Gray: Honoraria (self): AstraZeneca, Bristol-Myers Squibb, Takeda; Advisory / Consultancy: AstraZeneca, Bristol-Myers Squibb, Celgene, Takeda; Research grant / Funding (institution): Array, Merck, AstraZeneca, Genentech, Boehringer Ingelheim, Bristol-Myers Squibb. Y. Ohe: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca, Chugai, Dainippon Lilly, Ono, BMS Japan, Daiichi Sankyo, BI, Bayer, Ignyta, Pfizer, MSD, Taiho, Novartis, Kyorin, Kyowa Hakko Kirin, Takeda, Celltrion, Kissei, Amgen, Janssen, ROXO. B.C. Cho: Honoraria (institution), Advisory / Consultancy: Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Eli Lilly, Takeda; Speaker Bureau / Expert testimony: Novartis; Research grant / Funding (institution): Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD; Licensing / Royalties: Champions Oncology; Shareholder / Stockholder / Stock options: TheraCanVac Inc.. J. Vansteenkiste: Research grant / Funding (institution): MSD; Advisory / Consultancy: Apotex, AstraZeneca, Boehringer Ingelheim, MSD, Novartis, Roche; Speaker Bureau / Expert testimony: AstraZeneca, BMS, MSD, Roche. C. Zhou: Honoraria (self): Roche, Eli Lilly, Boehringer Ingelheim, Merck, Hengrui and Qiru. B. Chewaskulyong: Honoraria (self), Advisory / Consul<p>-Abstract Truncated-</p>

TOP: A Phase III, Multicentre, Randomized Controlled Study Comparing Osimertinib in Combination with Carboplatin and Pemetrexed to Osimertinib Monotherapy for Untreated Patients with Advanced Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) with Concurrent EGFR and TP53 Mutations.

P3.02b-096 Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results

Osimertinib Versus Standard of Care EGFR TKI As First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.

Early Clearance of Plasma EGFR Mutations As a Predictor of Response to Osimertinib and Comparator EGFR-TKiS in the Flaura Trial

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation

563P Real-world Effectiveness and Safety of First-Line Osimertinib for EGFR-mutated Advanced NSCLC in China (FLOURISH Study)

A Multi-Center Phase II Study of Toripalimab with Chemotherapy in Patients with EGFR Mutant Advanced NSCLC Patients Resistant to EGFR TKIs: Efficacy and Biomarker Analysis.

Osimertinib Plus Chemotherapy Versus Osimertinib for Patients with Advanced NSCLC Concomitant EGFR and TP53 Mutations: A Prospective Cohort Study

P1.01-112 Osimertinib Vs Standard of Care (soc) EGFR-TKI As First-Line Treatment in Chinese Patients with EGFRm Advanced NSCLC

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

1123P Real-world Outcomes of First-Line Osimertinib for EGFR Mutated Advanced NSCLC Patients in China: Interim Analysis of the FLOURISH Study

Pemetrexed and Platinum with or Without Pembrolizumab for Tyrosine Kinase Inhibitor (Tki)-Resistant, EGFR-mutant, Metastatic Nonsquamous NSCLC: Phase 3 KEYNOTE-789 Study

Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

562P First-line (1L) Osimertinib (osi) ± Platinum-Pemetrexed in Patients (pts) with EGFRm Advanced NSCLC: FLAURA2 China Cohort

Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment

Osimertinib Versus Comparator EGFR TKI As First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Final Overall Survival Results from the FLAURA Trial: a Phase III Study on Osimertinib in EGFR-Mutated Advanced Non-small Cell Lung Cancer

Osimertinib As Neoadjuvant Therapy in Patients with EGFR-mutant Resectable Stage II-IIIB Lung Adenocarcinoma (NEOS): A Multicenter, Single-Arm, Open-Label Phase 2b Trial.